Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Christian Dior, EADS, L’Oreal, Sanofi: French Equity Preview

Don't Miss Out —
Follow us on:

Feb. 6 (Bloomberg) -- The following companies’ shares may be active in Paris. Symbols are in parentheses after company names and prices are from the last close.

France’s CAC 40 Index rose 10.62, or 0.3 percent, to 4,047.21 in Paris. The SBF 120 Index rose 0.3 percent.

Christian Dior SA (CDI FP) The fashion company said 2010 net income was 1.26 billion euros ($1.71 billion), up from 695 million euros a year earlier. The shares fell 3 percent to 101.90 euros.

European Aeronautic, Defence & Space Co. (EAD FP): Parent company Airbus SAS’s Chief Executive Officer Tom Enders said the European plane maker won’t improve its bid to build a fleet of U.S. Air Force aerial refueling planes, Reuters reported. EADS stock lost 2 percent to 20.34 euros.

Fromageries Bel SA (FBEL FP): The cheese maker is among bidders for PAI Partners’ stake in Yoplait and may get backing from France’s FSI investment fund, Le Journal du Dimanche said, citing unidentified sources. The stock added 0.1 percent to 155.10 euros.

L’Oreal SA (OR FP): The world’s biggest cosmetics company’s Chairman Lindsay Owen-Jones will be replaced by Chief Executive Officer Jean-Paul Agon on March 17, Le Journal du Dimanche said, without saying where it got the information. Guylaine Mercier, a spokeswoman for L’Oreal, declined to comment. The shares climbed 1 percent to 88.77 euros.

Sanofi-Aventis SA (SAN FP): The drugmaker and Genzyme Corp. are likely to approve a takeover of the U.S. biotechnology company for about $74 a share plus additional payments tied to the performance of a drug, according to four people with knowledge of the plan. The shares rose 0.6 percent to 50.30 euros.

To contact the reporter on this story: Tara Patel in Paris at tpatel2@bloomberg.net

To contact the editor responsible for this story: Will Kennedy at wkennedy3@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.